Novartis AG Cash on Hand 2010-2023 | NVS

Novartis AG cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Novartis AG cash on hand for the quarter ending December 31, 2023 was $14.428B, a 23.78% decline year-over-year.
  • Novartis AG cash on hand for 2023 was $14.428B, a 23.78% decline from 2022.
  • Novartis AG cash on hand for 2022 was $18.93B, a 33.18% decline from 2021.
  • Novartis AG cash on hand for 2021 was $28.329B, a 145% increase from 2020.
Novartis AG Annual Cash on Hand
(Millions of US $)
2023 $14,428
2022 $18,930
2021 $28,329
2020 $11,563
2019 $11,446
2018 $15,964
2017 $9,485
2016 $7,777
2015 $5,447
2014 $13,862
2013 $9,222
2012 $8,119
2011 $5,075
2010 $8,134
2009 $17,449
Novartis AG Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $14,428
2023-09-30 $12,695
2023-06-30 $11,174
2023-03-31 $12,260
2022-12-31 $18,930
2022-09-30 $19,103
2022-06-30 $19,758
2022-03-31 $18,814
2021-12-31 $28,329
2021-09-30 $8,162
2021-06-30 $5,356
2021-03-31 $4,077
2020-12-31 $11,563
2020-09-30 $10,870
2020-06-30 $6,293
2020-03-31 $4,973
2019-12-31 $11,446
2019-09-30 $8,717
2019-06-30 $10,335
2019-03-31 $7,112
2018-12-31 $15,964
2018-09-30 $14,710
2018-06-30 $13,146
2018-03-31 $6,422
2017-12-31 $9,485
2017-09-30 $9,421
2017-06-30 $8,437
2017-03-31 $8,237
2016-12-31 $7,777
2016-09-30 $7,785
2016-06-30 $5,740
2016-03-31 $5,086
2015-12-31 $5,447
2015-09-30 $6,064
2015-06-30 $5,875
2015-03-31 $7,363
2014-12-31 $13,862
2014-09-30 $10,427
2014-06-30 $7,335
2014-03-31 $7,721
2013-12-31 $9,222
2013-09-30 $7,339
2013-06-30 $5,250
2013-03-31 $6,035
2012-12-31 $8,119
2012-09-30 $5,801
2012-06-30 $6,106
2012-03-31 $5,388
2011-12-31 $5,075
2011-09-30 $5,570
2011-06-30 $5,604
2011-03-31 $8,764
2010-12-31 $8,134
2010-09-30 $7,994
2010-06-30 $22,998
2010-03-31 $19,898
2009-12-31 $17,449
2009-09-30 $14,166
2009-06-30 $11,815
2009-03-31 $7,839
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.963B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $721.736B 120.19
Novo Nordisk (NVO) Denmark $562.737B 46.36
Johnson & Johnson (JNJ) United States $358.552B 14.27
Merck (MRK) United States $319.493B 84.10
AbbVie (ABBV) United States $296.619B 15.08
AstraZeneca (AZN) United Kingdom $215.324B 19.08
Pfizer (PFE) United States $149.151B 14.39
Sanofi (SNY) $117.880B 10.61
Innoviva (INVA) United States $0.930B 6.57